Olmesartan/Hydrochlorothiazide Clonmel (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxomil, the active ingredient in Olmesartan/Hydrochlorothiazide Clonmel, is an angiotensin II receptor blocker (ARB) presented as a oral tablet for hypertension management in adults. It combines olmesartan with a thiazide diuretic to lower blood pressure.

GNH USA supplies Olmesartan/Hydrochlorothiazide Clonmel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan/Hydrochlorothiazide Clonmel is prescribed for cardiovascular conditions that require blood‑pressure reduction. - Hypertension: Improves blood‑pressure control when monotherapy is insufficient. - Hypertensive heart disease: Reduces cardiac workload and risk of progression. - Chronic kidney disease with hypertension: Helps slow renal function decline associated with high blood pressure.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Increased urination - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal upset

Serious or Rare Side Effects: - Severe hypotension - Acute kidney injury - Hyperkalemia or severe electrolyte imbalance - Angio‑edema - Liver function abnormalities - Blood dyscrasias such as agranulocytosis

Before starting Olmesartan/Hydrochlorothiazide Clonmel, consider the following safety measures: - Renal function: Assess baseline kidney function and monitor periodically. - Electrolytes: Check serum potassium and sodium levels, especially in patients on other diuretics. - Blood pressure: Monitor for excessive drops, particularly after the first dose. - Pregnancy: Avoid use during pregnancy due to potential fetal risk. - Drug allergies: Discontinue if signs of angio‑edema or hypersensitivity develop. - Store at ambient temperature: Keep below 25°C in the original packaging, protected from moisture.

Olmesartan/Hydrochlorothiazide Clonmel can interact with several medicines; clinicians should review patient medication lists.

Major Interactions (Avoid): - Aliskiren (in diabetic patients): Increases risk of renal impairment and hyperkalemia. - Potassium‑sparing diuretics or supplements: May cause dangerous hyperkalemia. - NSAIDs (e.g., ibuprofen, naproxen): Can blunt antihypertensive effect and worsen kidney function.

Moderate Interactions (Monitor Closely): - Lithium: May increase lithium levels, risking toxicity. - Antidiabetic drugs: May enhance glucose‑lowering effect, requiring dose adjustment. - Other antihypertensives: May cause additive blood‑pressure lowering. - CYP450 inhibitors: May modestly raise olmesartan concentrations. - High‑dose corticosteroids: May counteract diuretic effect and affect electrolytes.